Ulnar Neuropathy at Elbow
Conditions
Brief summary
This study was be performed on 60 patients with ulnar neuropathy at elbow diagnosed clinically and by electrophysiology and/or ultrasonography selected from Physical medicine, Rheumatology & Rehabilitation Department, Faculty of Medicine, Tanta University. Patients were be randomly divided into 2 groups: Group I: will undergo a single ultrasound-guided deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve. PRP will be prepared by PRP method. Group II: will undergo a single ultrasound-guided deep perineural injection with 1ml corticosteroid (triamcinolone acetonide, 40mg/mL) mixed with 1ml lidocaine hydrochloride.
Interventions
Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
DRUGPRP
Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Patients with ulnar neuropathy at elbow diagnosed clinically and by electrophysiology and/or ultrasonography.
Exclusion criteria
1. Patients with severe ulnar neuropathy at elbow according to Gu's classification. 15 2. Brachial plexopathy, peripheral neuropathy, and cervical radiculopathy. 3. History of recent elbow trauma or operation. 4. Malignant neoplasm. 5. Pregnancy. 6. Bleeding Disorders. 7. Factors affecting nerve healing process e.g., tobacco use and systemic corticosteroid administration. 8. Contraindications for PRP injection: 1. Significant renal or hepatic dysfunction. 2. Critical thrombocytopenia. 3. Hemodynamic instability. 4. Septicemia. 5. Local infection at the site of the procedure. 6. Consistent use of nonsteroidal anti-inflammatory drugs within the last two weeks. 7. Local injection at the suspected treatment site within the last month. 8. Recent fever or illness. 9. Hemoglobin level \<10 g/dL. 10. Platelet dysfunction disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ultrasound cross sectional area of ulnar nerve at elbow after injection | 1, and 3 months after injection | — |
| Change in nerve conduction parameters of ulnar nerve at elbow after injection | 1 and 3 months after injection | Change in ulnar nerve conduction velocity and CMAP across elbow. |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 1 month after injection |
Countries
Egypt
Outcome results
None listed